Clinical outcomes in patients with faster advancing MS treated with teriflunomide in TEMSO and TOWER

被引：0
|
作者：
Kappos, L. [1 ]
Thangavelu, K. [2 ]
Cavalier, S. [2 ]
Truffinet, P. [3 ]
Comi, G. [4 ]
Miller, A. [5 ]
机构：
[1] Univ Hosp Basel, Basel, Switzerland
[2] Sanofi Genzyme, Cambridge, MA USA
[3] Sanofi Genzyme, Chilly Mazarin, France
[4] Univ Vita Salute San Raffaele, Milan, Italy
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2016年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P11185
引用
收藏
页码：197 / 197
页数：1
相关论文
共 50 条
  • [21] Clinical and MRI Outcomes from a Phase III Trial (TEMSO) of Oral Teriflunomide in Multiple Sclerosis with Relapses
    Miller, Aaron
    O'Connor, Paul
    Wolinsky, Jerry S.
    Confavreux, Christian
    Comi, Giancarlo
    Kappos, Ludwig
    Olsson, Tomas P.
    Benzerdjeb, Hadj
    Truffinet, Philippe
    Wang, Lin
    Freedman, Mark S.
    NEUROLOGY, 2011, 76 (09) : A545 - A545
  • [22] Teriflunomide is Effective in Reducing Brain Volume Loss in Previously Treated Patients: A Subgroup Analysis of TEMSO SIENA Data
    Freedman, M. S.
    Sprenger, T.
    Wuerfel, J.
    Miller, A. E.
    Thangavelu, K.
    Cavalier, S.
    Radue, E-W
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 336 - 336
  • [23] Teriflunomide is effective in reducing brain volume loss in previously treated patients: a subgroup analysis of TEMSO SIENA data
    Freedman, M. S.
    Sprenger, T.
    Radue, E-W
    Wuerfel, J.
    Miller, A. E.
    Thangavelu, K.
    Panzara, M. A.
    Cavalier, S.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 362 - 363
  • [24] Oral teriflunomide in patients with relapsing multiple sclerosis: baseline clinical features of patients in the TEMSO phase III trial
    O'Connor, Paul
    Confavreux, Christian
    Comi, Giancarlo
    Kappos, Ludwig
    Wolinsky, Jerry
    Olsson, Tomas P.
    Miller, Aaron
    Freedman, Mark S.
    MULTIPLE SCLEROSIS, 2008, 14 : S85 - S85
  • [25] Safety and tolerability of teriflunomide in MS patients in clinical practice
    Oreja-Guevara, C.
    Gonzalez-Suarez, I.
    Lopez de Velasco, V.
    Matias-Guiu, J.
    JOURNAL OF NEUROLOGY, 2014, 261 : S247 - S247
  • [26] miRNA profiling in Teriflunomide treated multiple sclerosis (MS) patients
    Paul, A.
    Rosso, M.
    Healy, B.
    Gandhi, R.
    Kivisakk, P.
    Glanz, B.
    Chitnis, T.
    Weiner, H.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 343 - 344
  • [27] Safety and tolerability of teriflunomide in MS patients in clinical practice
    Oreja-Guevara, C.
    Gonzalez-Suarez, I.
    Lopez de Velasco, V.
    Matias-Guiu, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 369 - 369
  • [28] Teriflunomide Is Effective in Reducing Brain Volume Loss in Previously Treated Patients: A Subgroup Analysis of TEMSO SIENA Data
    Freedman, Mark S.
    Sprenger, Till
    Radue, Ernst-Wilhelm
    Wuerfel, Jens
    Miller, Aaron E.
    Thangavelu, Karthinathan
    Cavalier, Steve
    Kappos, Ludwig
    NEUROLOGY, 2017, 88
  • [29] More MS Patients Remain Free from Disease Activity with Teriflunomide Versus Placebo in TEMSO, a Phase III Trial
    Kremenchutzky, Marcelo
    O'Connor, Paul W.
    Wolinsky, Jerry
    Confavreux, Christian
    Comi, Giancarlo
    Kappos, Ludwig
    Olsson, Tomas P.
    Truffinet, Philippe
    Dukovic, Deborah
    Miller, Aaron
    ANNALS OF NEUROLOGY, 2012, 72 : S72 - S72
  • [30] Pregnancy outcomes in female partners of male patients treated with teriflunomide or leflunomide (an in vivo precursor of teriflunomide)
    Vukusic, S.
    Hellwig, K.
    Truffinet, P.
    Benamor, M.
    Strattman, S.
    Afsar, S.
    Purvis, A.
    Poole, E. M.
    Coyle, P. K.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 620 - 620
12345